Drug intelligence / Profile preview

PTX-299

Development stage: Preclinical
Lead developer: PineTree Therapeutics
Modality: Small Molecules

Overview

PTX-299 is a preclinical-stage small molecule therapeutic candidate developed by Pinetree Therapeutics. It functions as an antagonist of the epidermal growth factor receptor (EGFR, also known as erbB1). By binding to EGFR, PTX-299 inhibits the receptor's activation and subsequent downstream signaling pathways that drive tumor cell proliferation, survival, and metastasis. The drug is primarily being investigated for the treatment of various neoplasms (cancers) where EGFR signaling plays a critical role in tumor growth and progression.

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on PTX-299.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTX-299.

Explore the full profile